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Abstract  
Ethnopharmacological relevance and aim: A decoction of the bark of Cylicodiscus gabunensis Harms is 
used as a traditional medicine in the treatment of malaria in Nigeria. This study aims to validate the 
antimalarial potency of this decoction in vitro against Plasmodium falciparum and define potential 
bioactive constituents within the C. gabunensis bark.  
Materials and methods: A bioassay-guided separation and fractionation protocol was applied to C. 
gabunensis extracts, exploiting the use of a Malaria Sybr Green I Fluorescence assay method to monitor 
antiproliferative effects on parasites as well as define 50% inhibition concentrations. Spectroscopic 
techniques, including GC-MS, TOF LC-MS and 1H NMR were used to identify phytochemicals present in 
bioactive fractions. Analogues of gallic acid were synthesized de novo to support the demonstration of the 
antimalarial action of phenolic acids identified in C. gabunensis bark. In vitro cytotoxicity of plant 
extracts, fractions and gallate analogues was evaluated against the HepG2 cell line. 
Results: The antimalarial activity of ethanolic extracts of C. gabunensis bark was confirmed in vitro, with 
evidence for phenolic acids, primarily gallic acid and close analogues such as ethyl gallate, likely 
providing this effect. Further fraction produced the most potent fraction with a 50% inhibitory 
concentration of 4.7 µg/ml. Spectroscopic analysis, including 1H NMR, LC-MS and GC-MS analysis of 
this fraction and its acid hydrolyzed products, indicated the presence of conjugates of gallic acid with 
oligosaccharides. The extracts/fractions and synthetic alkyl gallate showed moderate selectivity against P. 
falciparum. 
Conclusions: These results support the use of the bark of C. gabunensis as a traditional medicine in the 
treatment of human malaria, with phenolic acid oligosaccharide complexes evident in the most bioactive 
fractions.   
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1. Introduction 
Malaria imposes a significant health and socioeconomic impact within endemic regions across tropical 
and subtropical zones. In 2015 the World Health Organization (WHO) estimated there were some 214 
million new cases of malaria globally, resulting in approximately 438,000 deaths. Of these deaths, some 
90% occur within Sub-Saharan Africa (WHO, 2015). Yet over the last 15 years, the incidence of malaria 
and mortality figures, particularly in Africa, are falling significantly (Bhatt et al., 2015). This success 
follows from the introduction of interventions such as indoor residual spraying and insecticide treated bed 
nets, improved access to rapid diagnostic testing and the adoption of artemisinin combination therapies as 
the frontline antimalarial treatment. However, these successes are mirrored by increasing evidence of the 
development and spread of insecticide resistance and reports of artemisinin resistance within South East 
Asia (Ashley et al., 2014). The continued search for novel compounds with modes of action distinct to 
those of the current antimalarial pharmacopeia, include efforts to build on the success of plant-derived 
natural products, and their semi-synthetic analogues, in contributing new antimalarial leads. Traditional 
medicines have proven important in this search, with their importance demonstrated by the WHO which 
estimates that some 80% of populations in resource-poor regions depend upon these traditional medicines 
for antimalarial treatment. 
Cylicodiscus gabunensis Harms (CG) (Leguminosae) is a medicinal plant used for the treatment of fever, 
internal abscess, jaundice and malaria by the Ibibio of the Niger Delta region of Nigeria (Okokon et al., 
2006). The ethanolic stem bark extract of C. gabunensis shows schizontocidal activity in both early and 
established Plasmodium berghei infections in mice, with treatment showing an improved survival time 
comparable to that of chloroquine (Okokon et al., 2006). To date, several phytochemical studies on this 
plant have indicated the presence of triterpenes such as cylicodiscic acid (Tchivounda et al., 1990), 
triterpenoid saponins (Mkounga et al., 2010; Tchivounda et al., 1991; Tene et al., 2011) and cyclodione 
(Tane et al., 1995). However, the antimalarial compounds in the plant extract are still unknown. In this 
study, we confirm that extracts of C. gabunensis possess in vitro inhibitory effects against the blood 
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stages of the human malarial parasite P. falciparum Dd2, using a bioassay-guided fractionation procedure 
to isolate fractions which were then subjected to spectroscopic methods to identify compounds with 
potential antimalarial activity. Our studies suggest that phenolics, such as gallic acid and its derivatives 
may provide the active antimalarial constituent in C. gabunensis bark extracts. Furthermore, it is apparent 
that within the most potent fractions that phenolic-oligosaccharide conjugates likely provide the source of 
antimalarial potency. 
2. Materials and methods 
2.1 Plant materials and chemicals 
The bark of C. gabunensis was collected from the Imo state, Nigeria in September 2011. The plant was 
identified by Mr. H. Donyeachusim and a voucher specimen (UPH1028) was kept in the herbarium at the 
University of Port Harcourt, Nigeria. Solvents were supplied by Fischer Scientific (UK), other chemical 
were sourced from Sigma-Aldrich (UK). 
2.2 Extraction of plant materials  
Powdered C. gabunensis bark (120 g) was macerated over 48hrs in two liters of hexane, the process 
repeated and the filtrates combined and evaporated at 30°C under vacuum to yield the hexane extract 
(CGH, 0.9 g, 0.75%). The residue was extracted again by maceration using the same procedure with 70% 
ethanol; the filtrates were combined and dried at 45°C under vacuum to give the ethanol extract (CGE, 
11.3 g, 9.4 %). 
2.3. Fractionation and separation of bioactive compounds 
CGE (11 g) was dissolved in 700ml deionized water and partitioned with ethyl acetate and n-butanol 
sequentially to give the ethyl acetate fraction (CGEEA, 0.9g), butanol fraction (CGEBU, 8.3g) and 
aqueous fraction (CGEAQ, 1.6g). The CGEBU fraction was further fractionated on a silica gel glass 
column (35-75 μm; 4×60 cm) washed with solvent system CHCl3/MeOH/H2O (10: 1: 0.1) with increasing 
methanol (final concentration 100%) at a flow rate of 3 ml/min to give 10 pooled fractions (CGEBU-F(1-
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10)). Further separation of CGEBU-F10 was performed using preparative HPLC, yielding 8 sub-fractions 
CGEBU-F10-(1 to 8). A full description of the preparative HPLC is provided in the Supplementary 
materials.   
2.4 Spectroscopic and chemical analysis 
A full description of acid hydrolysis method, gas chromatography mass spectrometry (GC-MS), liquid 
chromatography mass spectrometry (LC-MS) and proton nuclear magnetic resonance (1H NMR) 
spectroscopic analysis are provided in the Supplementary materials. 
2.5 Chemical synthesis of gallic acid  derivatives 
Gallic acid and other phenolic acids were purchased from Sigma-Aldrich (UK). In addition, five gallic 
acid derivatives (Table 1) were prepared de novo for this study. Their synthesis and spectroscopic analysis 
is described in the Supplementary materials. 
2.6. In vitro determination of antimalarial activity 
The in vitro antimalarial activities of the plant extracts, fraction or pure compounds were assessed against 
intraerythrocytic P. falciparum culture (Dd2 strain) using the Sybr Green l Fluorescence assay as 
described (Smilkstein et al., 2004) and modified (Hasenkamp et al., 2013). CGE and its three fractions 
CGEEA, CGEBU, CGEAQ; CGH; and CGEBU-F1-10 were prepared as three concentrations in DMSO 
(100, 33.3, and 11.1 µg/ml) with DMSO not greater than 1% of the total concentration, while the most 
active fractions CGEBU-F10 and CGEBU-F10-7 were prepared using a serial two-fold dilution (200, 
100, 50, 25, 12.5, 6.25, 3.13, 1.56, and 0.78 µg/ml). Normalized fluorescence signals were determined 
against controls with 1% DMSO (100% growth) and exposure to a supralethal 10µM dose of chloroquine 
(0%growth). Determination of the 50% inhibitory concentration (IC50) was carried out with analysis of a 
log transformed concentration versus normalized fluorescence effect curve using GraphPad Prism 
software (v5.0) on data prepared from three independent biological replicates.  
2.7. In vitro cytotoxicity against HepG2 cells 
The in vitro activities of the plant extracts, fraction or pure compounds were assessed against HepG2 
(human liver carcinoma) using a modified alamar blue fluorescence assay as described (Horrocks et al, 
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2013). HepG2 cells were maintained in DMEM media supplemented with 10% (v/v) foetal bovine serum 
and 0.2% (v/v) of a penicillin (10 U/ml)/streptomycin (10 µg/ml) solution at 37°C in an atmosphere of 
5% CO2. 100 µL of cell suspension of HepG2 cells were seeded into a 96-well microplate at a density of 
1 × 105 cells/ml. After 24h of growth at 37°C, 100 µl of extracts or compounds in medium were added to 
the microplate wells, starting at either 150mM or 150µg/ml, to provide a twofold dilution series. 
Untreated controls were provided by cultures exposed to a 1% DMSO (100% growth) with a drug-treated 
control provided by exposure to 500nM actinomycin D (0% growth). The microplate was incubated at 
37˚C for a further 48 hrs before the cellular reductase activity was measured using an alamar blue® cell 
viability reagent (ThermoFisher). 20 µL of alamar blue was added into each well and mixed by shaking 
the plate. The fluorescence signal was measured at 570 nm using a Glomax multi-detection System after 6 
hours incubation. The 50% cytotoxicity concentration (CC50) was determined by analysis of a log 
transformed concentration versus normalized fluorescence signal curve using GraphPad Prism software 
(v5.0).  
 
3. Results 
3.1. Bioassay guided separations of extract of Cylicodiscus gabunensis bark 
A sample of C. gabunensis bark was extracted sequentially into hexane and 70% ethanol to produce CGE 
and CGH extracts. The anti-proliferative activity of these extracts was determined using in vitro growth 
inhibition assays of the Dd2 strain (chloroquine resistant) of P. falciparum, Chloroquine was used as a 
positive control (Table 1). Given the apparently greater antimalarial activity of CGE (IC50 20.8 µg/ml), 
further fractional separation in ethyl acetate (CGEEA), butanol (CGEBU) and water (CGEAQ) was 
undertaken. Here, the CGEBU fraction showed an approximate two-fold increase in antimalarial action 
over CGE (IC50 10.4µg/ml). The CGEBU fraction was subjected to column chromatography to yield 10 
sub-fractions, with fraction CGEBU-F10 the most potent with an IC50 of 6.5µg/ml. CGEBU-F10 was 
further separated using preparative HPLC (Figure S1) to yield eight sub-fractions. Of these, CGEBU-F10-
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7 was the most active, providing an IC50 of 4.7 µg/ml. Figure 1 shows a summary of the bioassay 
fractionation strategy employed. The cytotoxicity of CGE, CGEBU and CGEBU-F10 decreased in turn, 
with concurrent increases in antiplasmodial activity, although the selectivity (Selective index, SI 
CC50/IC50) against HepG2 cells only reached a modest value of >23. Insufficient CGEBU-F10-7 was 
available for cytotoxivity assays. 
 
Figure 1. Schematic illustrating the bioassay guided fractionation of C. gabunensis bark, indicating key 
fractionation methods and the phytochemical identified. The solvents used in the initial separation steps 
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are indicated using italics, with the IC50 of derived fractions indicated below each. Further column 
chromatography (generating 10 pooled fractions) of CGEBU and HPLC fractionation (8 pooled fractions) 
of CGEBU-F10 were used to derive the most potent fraction, CGEBU-F10-7. Where indicated with 
dotted lines, the spectroscopic methods listed were used to identify the key phytochemical components. 
In order to identify potentially bioactive compounds, GC-MS was initially applied to both CGEEA and 
CGEBU fractions after trimethylsilylation (Johnson-Ajinwo et al., 2015). These analyses (Figures S2 and 
S3; Table S1 and S2), indicate that 3,4,5-trihydroxybenzoic acid (gallic acid) as well as several fatty acids 
were present in both the CGEEA and CGEBU extracts, but also that additional benzoic acid derivatives, 
including 3-methoxy-4-hydroxybenzoic acid (vanillic acid, 0.4%), 3,4-dihydroxybenzoic acid 
(protocatechuic acid, 2%), and 3,4,5-trihydroxybenzoic ethyl ester (ethyl gallate, 2%), were also present 
in CGEEA.  
Independent confirmation of the potency of these benzoic acid derivatives was provided through 
additional growth inhibition assays of P. falciparum using commercially sourced materials (Table 1). 
These results indicated that either loss of a phenol group (e.g. vanillic acid) or substitutions to phenol 
groups of gallic acid (e.g. 3-methoxy-4-hydroxybenzoic acid or 3,4,5-trimethoxybenzoic acid) led to a 
decrease in antimalarial potency. Of note was the similar potency of ethyl gallate and propyl gallate to 
gallic acid, although these esterified derivatives are significantly less hydrophilic based on their predicted 
partition coefficients (LogP) (Table 1). To further explore this structure activity relationship, five 
additional esters were synthesized (Table 1, Table S3 and S4, Figure S4, and Supplementary materials), 
using gallic acid as a precursor, and their in vitro potency determined. These data indicate that whilst 
most have an IC50 comparable to that of ethyl gallate or propyl gallate, lauryl gallate, the most lipophilic 
derivative, was much lower at 2.2 µM, some 6-7 fold less than that of gallic acid. Unfortunately, the 
selectivity of these gallic acid derivatives remained only modest at best (Table 1) with alkyl and alkenyl 
gallates showed the best selectivity with selective indices between 10 and >17.  
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Table 1. In vitro antiplasmodial activity (IC50) and cytotoxicity (CC50) against HepG2 cells of extracts, 
fraction, gallic acid and its derivatives (along with standard deviation, SD, based on three biological 
repeats). Names of commercially sourced compounds or those synthesized (marked with* , Supplementary 
material) for this study are listed. Selective index, SI, is calculated as CC50/IC50. The LogP of compounds 
was predicted using Chemdraw software (PerkinElmer, USA). nd, not determined. 
 
 
Extract/fraction/compound IC50 ± SD CC50 ± SD SI Log P 
 
CGE 
(µg/ml) 
20.8 ± 1.8 (µg/ml) 
(µg/ml) 
59.8±14 (µg/ml) 
 
2.9 
 
nd 
CGEBU 10.4 ± 1.9 (µg/ml) 50.1±5.2 (µg/ml) 4.8 nd 
CGEBU-F10 6.5 ± 0.6 (µg/ml) ˃ 150 (µg/ml) ˃23 nd 
CGEBU-F10-7 4.7 ± 0.4 (µg/ml) nd nd nd 
 
 
Gallic acid  
 
(µM) 
26.8 ± 4.4 
 
(µM) 
11±1 
 
 
0.4 
 
 
0.42 
3,4-Dihydroxybenzoic acid  83.4 ± 10.0 ˃ 150 ˃1.8 0.81 
3-Methoxy-4-hydroxybenzoic 
acid 
71.2  ± 11.0 ˃ 150 ˃2.1 1.08 
3,4,5-Trimethoxybenzoic acid  112.3 ± 15.2 ˃ 150 ˃1.3 1.21 
Ethyl gallate  9.3 ± 3.1 ˃ 150 ˃16.1 1.02 
Propyl gallate  24.5 ± 2.9 ˃ 150 ˃6.1 1.51 
Propan-2-yl gallate* 13.9 ± 1.8 ˃ 150 ˃10.8 1.34 
2-Methylpropyl gallate* 16.9 ± 2.3 78±20 4.6 1.91 
2-Methylbutyl gallate* 11.8 ± 1.2 38±10 3.2 2.33 
3-Methylbut-2-en-1-yl gallate* 17.5 ± 2.2 87± 16 5.0 1.92 
3-Methylbutyl gallate* 8.8 ± 1.5 ˃ 150 ˃17.0 2.26 
Lauryl gallate  2.2 ± 0.2 30±2 13.6 5.27 
Chloroquine 0.17 ± 0.02 nd nd 5.00 
Actinomycin D nd 0.0038±0.0013 nd 3.80 
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3.2. Structural elucidation of the phytochemical content of CGEBU10-7 
GC-MS analysis of trimethylsilyl (TMSi) derivatives of CGEBU-F10-7 did not produce resolvable 
spectra, suggesting that the masses of the phytochemicals present were greater than that readily 
discernable using this approach. This was confirmed using an alternative LC-MS approach that revealed a 
complex mixture of compounds with masses ranging between 1000 and 1500 Da (Figure S5). Thus, the 
CGEBU-F10-7 fraction was subjected to acid hydrolysis, with GC-MS of the TMSi derivatives of these 
hydrolysed products carried out (Figure S6). This approach revealed the presence of gallic acid as well as 
three pairs of isomeric monosaccharides: α- and β-L-arabinose; α- and β-L-rhamnose; and α- and β-L-
glucose. It was considered likely that the acid hydrolysis procedure led to the anomerization of these 
sugars, which was subsequently confirmed in a subsequent experiment using commercially sourced sugar 
standards in water at 100°C.  In addition, 1H NMR (Figure S7) of CGEBU-F10-7 was carried out, 
revealing multiple peaks in the regions of δ 6-8 ppm and δ 3-6 ppm, supporting the existence of aromatic 
and sugar moieties in this complex fraction. In particular, two doublets at δ 5.2 (d, J = 3.7 Hz) and δ 4.4 
(d, J = 7.6 Hz) would support the presence of anomeric protons of α-L-arabinosyl and β-D-
glucopyranosyl moiety, respectively (Tene et al., 2011). Together, these data suggest the presence of 
gallic acid – oligosaccharide conjugates within the CGEBU-F10-7 fraction. 
4. Discussion 
Using a comprehensive bioassay-guided fractionation and isolation of the bark of C. gabunensis we 
provide evidence for the presence of antimalarial activity of both crude extracts, correlating with the 
previous observation of activity of an ethanolic extract against the murine malaria P. berghei (Okokon et 
al., 2006), but also refine this activity further to demonstrate specific activity of phenolic acids present in 
CGEBU and CGEEA. A preliminary structure activity relationship study of benzoic acid and gallate 
derivatives, including several synthesized de novo for this study, indicate that free hydroxyl groups on the 
aromatic ring for gallic acid and gallate esters are essential for their antimalarial effect. Gallic acid and 
protocatechuic acid have both previously been shown to moderate antimalarial activities against 
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chloroquine-resistant P. falciparum strain W2 (Garcia-Alvarez et al., 2013) with an additional study using 
ethyl gallate reporting an in vitro antiplasmodial effect of IC50 between 9 - 35 µM (Ramanandraibe et al., 
2008).  Results from these previous studies were in agreement with our own, with our study further 
suggesting that alkyl gallates, in particular lauryl gallate, have a greater antiplasmodial activity than gallic 
acid itself (Table 1). These promising observations, however, are moderated by the apparent restricted 
selectivity of these phenolic acids as compared to the HepG2 cell line. 
Bioassay guided fractionation gave a HPLC fraction (CGEBU-F10-7) which was most active. LC-MS, 
GC-MS and 1H NMR analysis suggested that conjugates of oligosaccharide with gallic acid may be 
present in this fraction. However, the exact linkage between the monosaccharides and gallic acid needs 
further detailed study. Previously an oligosaccharide derivative (a resin glycoside, crypthophilic acid C) 
from Scrophularia cryptophila showed antimalarial activity with IC50 value of 4.2 µg/ml (Tasdemir et al., 
2008). Ellagic acid (a dimer of gallic acid) and a galloyl glycoside from Tristaniopsis calobuxus bark 
extract had IC50 values of 0.5 and 3.2 µM, respectively (Verotta et al., 2001). 1-O-galloyl-6-O-luteoyl-α-
D-glucose from Phyllanthus niruri also showed very low IC50 (1.4 µg/ml) (Subeki et al., 2005). Together 
with our own data, these observations suggest that a galloyl moiety within the bark of C. gabunensis 
likely supplies the observed antimalarial activity of this traditional medicine. 
 
5. Conclusions 
Bioassay guided fractionation of C. gabunensis extract yielded fractions with increasing antimalarial 
activity and selectivity of action. Using spectroscopic and chemical methods, gallic acid, ethyl gallate and 
benzoic acids were demonstrated to be present and likely contributed to this antimalarial activity. The 
likely bioactive component in this traditional medicine for the treatment of malaria is a galloyl glycoside 
conjugate.   
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